Skip to content
DataLookout
Menu

NCT06217185

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

StatusActive, Not Recruiting
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 19 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

PFS
Timeframe: 24months

Secondary (5)

CNS-PFS
ORR
DCR
OS
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events

Arms and interventions

Experimental armExperimental

Pyrotinib, Trastuzumab Combined With Taxanes \*When taxane drugs are discontinued (after completing 6-8 cycles of treatment or due to intolerance), the therapy can be continued with the combination of metronomic capecitabine and trastuzumab, along with pyrotinib.

Drugs: Pyrotinib, Trastuzumab, Taxanes, Capecitabine

Sites

1 site in 1 country

  • The Fourth Hospital of Hebei Medical UniversityShijiazhuang, Hebei, China